POLBF - Poolbeg Pharma continuing its campaign to find a partner for POLB001
(NewsDirect)
Proactive Research Analyst Daniel Appiahspeaks to Thomas Warner at the London Studio after publishing a newresearch note on clinical-stage biopharmaceutical company PoolbegPharma.
Appiah starts by explainingthe scale of the opportunity that Poolbeg is pursuing with its leadcompound POLB001 in acute influenza, noting the estimated 3-5 millionsevere influenza cases globally per annum. The company is broadeningits reach by expanding the compound into the oncology sector.Additionally, Appiah highlights Poolbeg's recent developments inthe oral vaccine sector.
Thecompany's oral delivery platform is in the limelight following anannouncement about their collaboration with an undisclosedNASDAQ-listed biopharma enterprise. The partnership aims to utilisePoolbeg's oral drug delivery technology to optimise drugformulations targeting metabolic conditions.
Significantly, this venture could pave theway for Poolbeg to tap into the burgeoning market for GLP-1 injectabletreatments for obesity and diabetes, which is expected to growsignificantly in the coming years.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.